Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients

• DOI: 10.3892/ol.2014.2392
• Publication Date: 2014-07-30T08:50:29Z
• Authors: JULIETA AFONSO; ADHEMAR LONGATTO-...; VITOR MOREIRA DA ...; TERESINA AMARO; LÚCIO L. SANTOS
• Keywords: Tumour heterogeneity; CD31; Anatomical pathology

Urothelial bladder carcinoma (UBC) is heterogeneous in its pathology and clinical behaviour. Evaluation of prognostic predictive biomarkers necessary, order to produce personalised treatment options. The present study used immunohistochemistry evaluate UBC sections containing tumour non-tumour areas from 76 patients, for the detection p-mTOR, CD31 D2-40 (blood lymphatic vessels identification, respectively). Of sections, 36 20% were scored positive p-mTOR expression, respectively. Immunoexpression was observed umbrella cells urothelium, all cell layers non-muscle-invasive (NMI) tumours (including expression superficial cells), spots muscle-invasive (MI) tumours. Positive decreased pT1/pTis pT3/pT4 tumours; however, few cases had worse survival rates, with 5-year disease-free being significantly lower. Angiogenesis occurrence impaired that did not express p-mTOR. In conclusion, likely a reflection their metabolic plasticity, extension inner urothelium NMI consistent an enhanced malignant potential. MI absence remaining intriguing requires further research. Additional studies regarding up- downstream effectors mTOR pathway should be conducted.